$Allogene Therapeutics Inc.(ALLO)$
📈 🔺🅱🆄🅻🅻🅸🆂🅷 🔺📈
I opened positions during Open Market 04Nov24 in this small cap crap bio JANUARY EFFECT stock.
🎯🦠🚀🦠🎯 ALLOgenius in the Biotech Breakout Zone! Are We Ready for a January Jump? 🎯🦠🚀🦠🎯
Kia ora Tiger traders!
Allogene Therapeutics (ALLO) is creating waves 🌊 in the biotech space, with its current price at $3.01 (post market 04Nov24) and a potential upside of 216.94%! Is this the next big biotech play, or just a flash in the petri dish? 🧫 Let’s break it down with the latest insights and a touch of humour!
💡 Key Metrics to Watch
• Current Price: $3.00 📈
• Analyst Target Range: $3.50 (Low) - $14.00 (High)
• Average Price Target: $9.51
• This could be a “cell-ebration” in the making!
• Buy-Hold-Sell Ratings:
• 🟢 Buy: 47%
• 🟠 Hold: 24%
• 🔴 Sell: 0%
🔍 What the Analysts Are Saying
Big names are rallying behind ALLO with bullish ratings:
• Truist Financial: Reiterated “Buy” with a $14.00 target!
• Citigroup: Boosted target to $8.00—another strong “Buy” signal!
• Canaccord Genuity: Despite a drop from $35 to $14, they’re still holding the “Buy” stance.
Hedge funds aren’t missing a beat either. They’ve been upping their stakes by over 76% in the last quarter! Institutional investors now hold 83.63% of ALLO stock, a promising sign of long-term potential.
📊 Chart Check: The Path to $5.50
ALLO’s chart is showing a fascinating pattern, with $3.00 acting as solid support and a cup formation pointing towards a $5.50 target as early as January! The “Small Cap January Effect” has historically boosted stocks like ALLO, and with this setup, we could see a biotech breakout to kick off 2024.
Could this “cup” be the secret recipe for a January lift?
🥇 How ALLO Stacks Up Against Competitors
Let’s see how ALLO compares with some biotech players:
• CRISPR Therapeutics (CRSP):
• 🟢 Buy: 60%
• 🟠 Hold: 30%
• 🔴 Sell: 10%
• Intellia Therapeutics (NTLA):
• 🟢 Buy: 50%
• 🟠 Hold: 40%
• 🔴 Sell: 10%
• Editas Medicine (EDIT):
• 🟢 Buy: 45%
• 🟠 Hold: 45%
• 🔴 Sell: 10%
With its unique approach to allogeneic T-cell therapy, ALLO stands out as a potential game-changer in the biotech world, even against these heavy hitters.
🎬 Fun Fact:
Did you know? The “January Effect” has historically sparked small-cap rallies as new fund allocations pour in. Could ALLO be the biotech stock to watch this New Year? I believe so!
Hey Tiger Traders, what’s your take? Are you all-in on ALLO for a breakout January, or is it just “gene” therapy for wishful thinkers? 🎩
@TigerGPT, give us your biotech forecast, how high could ALLO go in Q1 2024?
Happy trading ahead. Cheers, BC 🍀🍀🍀
@Tiger_comments @TigerObserver @TigerWire @TigerStars @TigerPM @TigerPicks @Daily_Discussion @TigerGPT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Allogene Therapeutics Inc. (ALLO) Stock Analysis
Company Overview: Allogene Therapeutics is a biotech company focused on the development of allogeneic T-cell therapies for the treatment of cancer. The company is involved in the research, development, and commercialization of off-the-shelf CAR T-cell therapies.
Earnings Forecast: For the fiscal year 2024, Allogene Therapeutics is expected to report an EPS (earnings per share) of -1.49 USD. The forecasted gross income is 64.38 thousand USD, and the forecasted EBIT (earnings before interest and taxes) is -283.27 million USD.
Analyst Recommendation: Analysts have provided 5 recommendations for Allogene Therapeutics, including 8 buy ratings and 4 hold ratings.
Analyst Target Price: The mean target price estimated by 12 analysts is 9.51 USD, with a low target of 3.50 USD and a high target of 14.00 USD.
Capital Flow Data: The 5-day capital flow data indicates that on October 28, there was a net outflow of 144.56 thousand units (K), followed by net inflows of 374.35K, 1,188.75K, and net outflows of 502.88K and 84.85K on October 29, 30, 31, and November 1, respectively.
Profiteer Ratio: The profiteer ratio on November 4 was 0.9673.
Resistance and Support Price: The resistance price on November 4 was 3.0 USD, and the support price was 2.71 USD.
Recent Earnings Results: Allogene Therapeutics reported an EPS of -0.35 USD for the second quarter of 2024. Notable financial ratios include a return on equity of -54.37%, a quick ratio of 11.97, and a current ratio of 12.25.
Stock Price: As of November 5, the stock price of Allogene Therapeutics was 3.0 USD.
Analyst Ratings and News: Truist Financial has reiterated a "Buy" rating with a target price of 14.00 USD. Citigroup has boosted their target price to 8.00 USD, also indicating a "Buy" signal. Canaccord Genuity maintains a "Buy" rating despite a drop in the target price from 35.00 USD to 14.00 USD.
Comparison with Competitors: Compared to other biotech players such as CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine (EDIT), Allogene Therapeutics stands out with its unique approach to allogeneic T-cell therapy.
January Effect: The January Effect historically sparks small-cap rallies as new fund allocations pour in. This could potentially benefit stocks like Allogene Therapeutics, leading to a biotech breakout at the beginning of 2024.
Stock Forecast: Given the available information, it is difficult to provide a specific price target for ALLO in Q1 2024. The average analyst target price is 9.51 USD, suggesting potential upside. However, please note that stock forecasts are subject to market volatility and other factors, and it is recommended to conduct independent research and analysis before making investment decisions.
Disclaimer: The information provided above is for reference purposes only and should not be considered as investment advice. Investing in stocks involves inherent risks, and the prices of stocks may fluctuate. It is important to conduct thorough research and analysis before making any investment decisions.
Great article, would you like to share it?
Great article, would you like to share it?